Pászty Katalin, Verma Anil K, Padányi Rita, Filoteo Adelaida G, Penniston John T, Enyedi Agnes
National Institute of Haematology and Immunology, Daroczi ut 24, Budapest 1113, Hungary.
J Biol Chem. 2002 Mar 1;277(9):6822-9. doi: 10.1074/jbc.M109548200. Epub 2001 Dec 20.
The plasma membrane Ca(2+) pump (PMCA) is an essential element in the complex of mechanisms that maintain low intracellular Ca(2+) concentration in the living cell. This pump is tightly regulated by calmodulin through binding to a high affinity calmodulin-binding domain at the C terminus that also serves as an autoinhibitor of the enzyme. Inspection of the C terminus of hPMCA4b, the most widely distributed form of PMCA, revealed a caspase-3 consensus sequence ((1077)DEID(1080)) just a few residues upstream of the calmodulin-binding domain. We demonstrate here that, in the early phase of apoptosis, hPMCA4b is cleaved at aspartic acid Asp(1080) in hPMCA4b-transfected COS-7 cells or in HeLa cells that naturally express this protein. This cleavage of hPMCA4b produces a single 120-kDa fragment that is fully active in the absence of calmodulin, because the whole inhibitory region downstream of the (1077)DEID(1080) sequence is removed. Our experiments show that caspase-3 or a caspase-3-like protease is responsible for the formation of the constitutively active 120-kDa PMCA4b fragment: 1) Pretreatment of the cells with the caspase-3 inhibitor Z-DEVD-FMK (benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone) was able to block the production of the 120-kDa fragment. 2) In vitro treatment of hPMCA4b with recombinant caspase-3 also generated a 120-kDa cleavage product, consistent with that seen in cells undergoing apoptosis. 3) Mutants in which the caspase-3 consensus sequence was altered ((1077)AEID(1080), (1077)DEIA(1080), and (1077)AEIA(1080) mutants) were resistant to proteolysis. Based on these data, we conclude that hPMCA4b is a newly identified, natural caspase-3 substrate. We suggest that a constitutively active form of this protein, responding much faster to an increase in Ca(2+) concentration than the autoinhibited form, may have an important role in regulating intracellular Ca(2+) concentration in the apoptotic cell.
质膜钙泵(PMCA)是维持活细胞内低钙浓度的复杂机制中的一个重要组成部分。该泵通过与位于C端的高亲和力钙调蛋白结合结构域结合而受到钙调蛋白的严格调控,该结构域同时也是该酶的自身抑制剂。对PMCA分布最广泛的形式hPMCA4b的C端进行检查发现,在钙调蛋白结合结构域上游仅几个残基处有一个半胱天冬酶-3共有序列((1077)DEID(1080))。我们在此证明,在凋亡早期,在转染了hPMCA4b的COS-7细胞或天然表达该蛋白的HeLa细胞中,hPMCA4b在天冬氨酸Asp(1080)处被切割。hPMCA4b的这种切割产生一个120 kDa的片段,该片段在没有钙调蛋白的情况下具有完全活性,因为(1077)DEID(1080)序列下游的整个抑制区域被去除。我们的实验表明,半胱天冬酶-3或类似半胱天冬酶-3的蛋白酶负责组成型活性120 kDa PMCA4b片段的形成:1)用半胱天冬酶-3抑制剂Z-DEVD-FMK(苄氧羰基-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-氟甲基酮)预处理细胞能够阻断120 kDa片段的产生。2)用重组半胱天冬酶-3对hPMCA4b进行体外处理也产生了一个120 kDa的切割产物,这与在凋亡细胞中观察到的一致。3)半胱天冬酶-3共有序列发生改变的突变体((1077)AEID(1080)、(1077)DEIA(1080)和(1077)AEIA(1080)突变体)对蛋白水解具有抗性。基于这些数据,我们得出结论,hPMCA4b是一种新鉴定的天然半胱天冬酶-3底物。我们认为,这种蛋白的组成型活性形式对钙浓度增加的反应比自身抑制形式快得多,可能在调节凋亡细胞内的钙浓度方面具有重要作用。